ALDX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AL

Mkt Cap

$42.2M

Volume

1.76M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekUltragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals.Zacks Investment Research · Oct 15, 2026

Here's Why You Should Add ANRO Stock to Your Portfolio NowAlto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth.Zacks Investment Research · Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalSyndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028.Zacks Investment Research · Oct 14, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyPrime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.Zacks Investment Research · Oct 12, 2026

PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowPMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.Zacks Investment Research · Oct 12, 2026

argenx Meets Primary Endpoint in Phase II Celiac Disease Studyargenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease.Zacks Investment Research · Oct 9, 2026

EDIT Set to Begin First-in-Human Study in HypercholesterolemiaEditas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027.Zacks Investment Research · Oct 9, 2026

Here's Why You Should Add LPCN Stock to Your Portfolio NowLipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis.Zacks Investment Research · Oct 8, 2026

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashUltragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing.Zacks Investment Research · Oct 8, 2026

ETON Stock Surges 108% in Six Months: Here's What You Need to KnowEton Pharmaceuticals has gained 108% over six months, driven by 99% Q2 product sales growth and successful Hemangeol relaunch. The company raised 2026 revenue guidance to above $145 million with 35%+ adjusted EBITDA margins. Pipeline expansion including new launches and late-stage candidates like ASN-001 provide additional growth opportunities.Zacks Investment Research · Oct 7, 2026

AL

ALDXAldeyra Therapeutics, Inc.

ALDX

Pay with—

Available Balance0.00

Your PositionYou don't own any ALDX yet.

Related Tickers

Earnings